Featured Insight
Article: Accelerated Approvals in Oncology: Benefits, Risks, and the Way Forward With Dr. Jason Mouabbi, Dr. Ross Maclean, and Michael Glover
Accelerated FDA approvals are under scrutiny and at the center of many debates. Explore the complexities, benefits, and risks of accelerated approvals with Ross Maclean, EVP at PRECISIONheor & Head of Medical Affairs at Precision Value & Health, in an insightful discussion alongside Dr. Jason A. Mouabbi, Breast Medical Oncologist at MD Anderson.
Article: Doubling Down on Deep Customer Insights to Inform Value Demonstration
An expert view from Ross Maclean, Head of Medical Affairs and Jon Bambalas, SVP, Business Development, Precision Value & Health, on how insights from patient-level health insurance benefits data can serve the pharmaceutical industry – namely, how coverage insights can inform the generation of evidence to demonstrate to payers and providers the value of a specific treatment.
On Demand: Quantifying Health Equity Impact of Innovative Healthcare Interventions
The COVID-19 pandemic laid bare disparities in access to quality healthcare and resources that have led to poor outcomes among racial and ethnic minorities, socioeconomically vulnerable individuals, and populations in rural areas. With a renewed and keener scrutiny of health equity issues, the distributional consequences of a new intervention across subgroups should come to the forefront of discussions about value in health. Join Precision HEOR for a webinar about studying the health equity impacts of new interventions. We will outline the conceptual basis of how health interventions can affect health equity and consider distributional cost-effectiveness analysis with decision-analytic models as a practical approach to assess this quantitatively. We will discuss the evidence needs and typical gaps for new interventions and how to optimize the use of existing data. The discussion will conclude with a live Q&A.
Article: Doubling Down on Deep Customer Insights to Inform Value Demonstration
An expert view from Ross Maclean, Head of Medical Affairs and Jon Bambalas, SVP, Business Development, Precision Value & Health, on how insights from patient-level health insurance benefits data can serve the pharmaceutical industry – namely, how coverage insights can inform the generation of evidence to demonstrate to payers and providers the value of a specific treatment.
Poster Presentation: San Antonio Breast Cancer Symposium (SABCS) 2023
Gilead Sciences, Inc. will present new data at the San Antonio Breast Cancer Symposium (SABCS) 2023 supporting the use of Trodelvy® (sacituzumab govitecan-hziy) in certain metastatic triple-negative breast cancer (mTNBC) and pre-treated HR+/HER2- metastatic breast cancer (mBC) patients. Precision's research with Gilead Sciences on "Understanding Clinical Meaningfulness in Metastatic Breast Cancer Treatment Decision-Making" will be presented during Poster Session 1: Poster # PO1-10-06 on Wednesday, Dec. 6 at 12:00 PM. Co-authored by Meaghan Roach, Rozanne Wilson, Suepattra May-Slater, Melissa Maravic and Emily Freeman.
Short Courses: ISPOR EU 2023
Precision will be at ISPOR Europe November 12-15, 2023. Don't miss our two Short Courses.
On Demand: Quantifying Health Equity Impact of Innovative Healthcare Interventions
The COVID-19 pandemic laid bare disparities in access to quality healthcare and resources that have led to poor outcomes among racial and ethnic minorities, socioeconomically vulnerable individuals, and populations in rural areas. With a renewed and keener scrutiny of health equity issues, the distributional consequences of a new intervention across subgroups should come to the forefront of discussions about value in health. Join Precision HEOR for a webinar about studying the health equity impacts of new interventions. We will outline the conceptual basis of how health interventions can affect health equity and consider distributional cost-effectiveness analysis with decision-analytic models as a practical approach to assess this quantitatively. We will discuss the evidence needs and typical gaps for new interventions and how to optimize the use of existing data. The discussion will conclude with a live Q&A.
Webinar: Quantifying Health Equity Impact of Innovative Health Care Interventions
The COVID-19 pandemic laid bare disparities in access to quality healthcare and resources that have led to poor outcomes among racial and ethnic minorities, socioeconomically vulnerable individuals, and populations in rural areas. With a renewed and keener scrutiny of health equity issues, the distributional consequences of a new intervention across subgroups should come to the forefront of discussions about value in health. Join PRECISIONheor for a webinar about studying the health equity impacts of new interventions. We will outline the conceptual basis of how health interventions can affect health equity and consider distributional cost-effectiveness analysis with decision-analytic models as a practical approach to assess this quantitatively. We will discuss the evidence needs and typical gaps for new interventions and how to optimize the use of existing data. The discussion will conclude with a live Q&A.
On-Demand Webinar – A Novel Data and Analytics-Informed Approach to Launch Excellence
Launching a therapy has become increasingly challenging, with only 34% of launches meeting their year-one goals (Evaluate Pharma, McKinsey). In addition, launches have also become more complex, with additional stakeholders to consider as well as the careful navigation of siloed, enterprise-wide functions and dynamic, fragmented data solutions. Not surprisingly, the path to a successful launch can be very narrow.
Article: Accelerated Approvals in Oncology: Benefits, Risks, and the Way Forward With Dr. Jason Mouabbi, Dr. Ross Maclean, and Michael Glover
Accelerated FDA approvals are under scrutiny and at the center of many debates. Explore the complexities, benefits, and risks of accelerated approvals with Ross Maclean, EVP at PRECISIONheor & Head of Medical Affairs at Precision Value & Health, in an insightful discussion alongside Dr. Jason A. Mouabbi, Breast Medical Oncologist at MD Anderson.
Article: Doubling Down on Deep Customer Insights to Inform Value Demonstration
An expert view from Ross Maclean, Head of Medical Affairs and Jon Bambalas, SVP, Business Development, Precision Value & Health, on how insights from patient-level health insurance benefits data can serve the pharmaceutical industry – namely, how coverage insights can inform the generation of evidence to demonstrate to payers and providers the value of a specific treatment.
On Demand: Quantifying Health Equity Impact of Innovative Healthcare Interventions
The COVID-19 pandemic laid bare disparities in access to quality healthcare and resources that have led to poor outcomes among racial and ethnic minorities, socioeconomically vulnerable individuals, and populations in rural areas. With a renewed and keener scrutiny of health equity issues, the distributional consequences of a new intervention across subgroups should come to the forefront of discussions about value in health. Join Precision HEOR for a webinar about studying the health equity impacts of new interventions. We will outline the conceptual basis of how health interventions can affect health equity and consider distributional cost-effectiveness analysis with decision-analytic models as a practical approach to assess this quantitatively. We will discuss the evidence needs and typical gaps for new interventions and how to optimize the use of existing data. The discussion will conclude with a live Q&A.
Download Now: Precision August Events Calendar
Don’t miss any of our upcoming Precision Value & Health events! Check out our monthly marketing activities calendar to stay ahead of upcoming dates!
Incorporating Disease Transmission Dynamics Into Value Assessment
With focus in the COVID-19 pandemic shifting to treatments and managing severe forms of the disease, it's important to understand how health economists capture these dynamics to estimate the value of antiviral treatments. Precision's Jacquelyn W. Chou, Marissa Baker-Wagner, Marlon Graf, Zachary Heim, and T. Joseph Mattingly II provide recommendations for aligning the actual practice of value assessment of antivirals with best practice guidelines
Three Essential Tactics for Successful Drug Commercialization
One of the top tradeoffs faced by clinical stage biotech and pharmaceutical firms in raising capital to fund their clinical trial programs is the question of when and how to build a commercialization strategy, including navigating the complex work of securing market access. Precision's Ross Maclean and co-author Liz Turner discuss three high-value tactics that should be conducted early to avoid costly missteps that could impact product success.
Seven Strategies for Succeeding as a Small Fish in a Big Pond
Emerging biotech organizations have had to become both resourceful and creative since the start of the COVID-19 pandemic. At the same time, Big Pharma and the medical device firms have turned around COVID-19 diagnostics, vaccines, and therapeutics at a stunningly impressive pace. The pressure on emerging and small biotech companies to do more with less and maximize results is only projected to continue. Precision's Ross Maclean and co-author Liz Turner identify seven key attributes that favor the smaller biotech.
Featured Expert: Walter Bouwmeester
This month, PRECISIONheor highlights Director, Walter Bouwmeester.
Insights90: Marlon Graf
In these past few years, life has been filled with uncertainty. Listen as Precision’s Marlon Graf discusses how PRECISIONheor finds ways to deal with uncertainty in healthcare decision making in this Insights90.
PRECISIONheor Executive Summary: NICE-UK Strategy 2021-2026
Recently, the National Institute for Health and Care Excellence (NICE) published a detailed strategy plan, outlining its vision during the next five years. Included in this report are new guidelines for technology evaluation, evidence standards, guidance adoption, and real-world data and research, which are applicable to all stakeholders, including the life science industry, regulators, healthcare providers, patients, and the public.
Featured Expert: Steve Sison
This month PRECISIONheor would like to highlight the work and expertise of Senior Director Steve Sison.
Featured Expert: Suepattra May-Slater
This month PRECISIONheor would like to highlight the work and expertise of Senior Principal Scientist Suepattra May-Slater.
Featured Expert: Meena Venkatachalam
This month PRECISIONheor would like to highlight the work and expertise of Senior Director Meena Venkatachalam.
The Complementary Relationship Between Quantitative and Qualitative Research Methods in Enhancing Understanding of Treatment Decisions, Outcomes, and Value Assessment
Quantitative studies are the gold standard for establishing causality and drawing conclusions that can be generalized beyond the population studied. However, quantitative research methods also often lack contextual considerations and perspectives that can be further informed by qualitative approaches.
PRECISIONheor Featured Rare Disease Publications
The high costs often associated with treatments for rare diseases can make it challenging for patients to gain access to these life-changing therapies. PRECISIONheor experts have led research in a number of innovative studies on rare diseases to help get these treatments into the hands of the patients that need them the most.
Experts Discuss How Expanding Traditional Value Frameworks Can Address Inequities in Health Outcomes
Expanding traditional value frameworks to include inequality and factors that contribute to this is the first step to addressing disparities in health outcomes.
Welcome: Hema Viswanathan, PhD
Precision is excited to welcome Hema Viswanathan as Vice President, PRECISIONheor. With more than 15 years experience in the industry, Hema brings exceptional insights and strategic vision. Hema will support cross functions in health economics and outcomes research (HEOR) from RWE, Evidence Synthesis and Modeling. Welcome to the Precision team!
Precision at ISPOR Europe 2019
Precision is excited to be headed to Copenhagen, November 2nd - 6th! Be sure to catch our scientific presentations at the conference, and meet our experts!
Meet with Precision at ISPOR in New Orleans
Meet our subject matter experts to hear how we can support you with health technology assessments, new models for evidence synthesis, and defending the value of your treatments to payers.
AMCP taps precision to lead value-based contracting workshop
Hosted by the AMCP in collaboration with Precision Xtract, this unique half-day workshop will assemble managed care and health plan experts to explore different types of value-based contracts.
